A selective growth hormone secretagogue and ghrelin receptor agonist notable for stimulating GH release with minimal effects on cortisol or prolactin.
Sourced from Ascension Peptides. Verified purity, third-party tested. COA included.
Buy Now →Ipamorelin is a synthetic pentapeptide growth hormone secretagogue (GHS) with the amino acid sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2, where Aib denotes alpha-aminoisobutyric acid and D-2-Nal denotes D-naphthylalanine at position 2. This five-residue sequence — among the shortest peptides known to produce meaningful GH secretagogue activity — was developed through systematic structure-activity relationship optimization at Novo Nordisk in the late 1990s, building on earlier work with larger GHS peptides such as GHRP-6 and GHRP-2.
The defining characteristic that distinguishes ipamorelin from earlier generation growth hormone releasing peptides is its remarkable selectivity profile. Most prior GHS compounds, including GHRP-6 and hexarelin, produced not only GH release but also significant elevations in cortisol, prolactin, and adrenocorticotropic hormone (ACTH) — side effects arising from off-target activation of related receptor systems. Ipamorelin was specifically engineered to maintain high affinity at the ghrelin receptor (also called the growth hormone secretagogue receptor 1a, or GHS-R1a) while dramatically reducing activity at the receptor systems responsible for cortisol and prolactin release. Published receptor selectivity studies demonstrated that ipamorelin produced GH release with minimal or no statistically significant elevation in cortisol or prolactin at doses producing maximal GH responses — a selectivity profile that had not been achieved by any prior compound in this class.
This selectivity makes ipamorelin a uniquely useful research tool for isolating the effects of GH axis stimulation from the confounding hormonal effects that complicated interpretation of studies using less selective GHS compounds. When researchers want to study the consequences of increased GH pulsatility without simultaneously perturbing the HPA axis or prolactin-mediated signaling, ipamorelin is the preferred pharmacological tool.
Ipamorelin has not received regulatory approval for any clinical indication in any major jurisdiction and remains an investigational compound used in preclinical research, early-phase clinical investigation, and compounding pharmacy preparations for off-label clinical use in some countries. It has been the subject of clinical development by several companies — most notably Helsinn Healthcare under the development code RC-1291 for cancer-related muscle wasting (cachexia) — though no program has yet completed Phase 3 trials to regulatory submission. Researchers can access the full receptor binding profile and comparative selectivity data for ipamorelin in the peptide database.
Ipamorelin’s mechanism of action begins with binding to the ghrelin receptor, officially designated GHS-R1a (growth hormone secretagogue receptor subtype 1a). This receptor is expressed in highest abundance in pituitary somatotroph cells — where GH secretion originates — and additionally in the hypothalamus, where it modulates GHRH and somatostatin release, and in peripheral tissues including the stomach, pancreas, liver, and adipose tissue. The GHS-R1a is a seven-transmembrane-domain G protein-coupled receptor that was initially identified as an “orphan” receptor in the early 1990s; its endogenous ligand, the appetite-stimulating hormone ghrelin, was not discovered until 1999, nearly five years after the receptor was cloned.
Ipamorelin’s binding to GHS-R1a differs from ghrelin’s binding in important ways. Native ghrelin is a 28-amino acid peptide with an unusual acyl modification (an octanoyl group on serine-3) that is essential for receptor activation; ipamorelin achieves GHS-R1a activation through a completely different structural interaction, reflecting the receptor’s capacity to accommodate diverse pharmacophores. Upon ipamorelin binding, GHS-R1a couples primarily to the Gq/11 protein subunit (in contrast to GHRH receptor’s Gs coupling), activating phospholipase C beta (PLCβ). PLCβ cleaves phosphatidylinositol 4,5-bisphosphate (PIP2) into diacylglycerol (DAG) and inositol trisphosphate (IP3). IP3 binds receptors on the endoplasmic reticulum, triggering calcium release into the cytoplasm. This intracellular calcium surge is the primary trigger for GH secretory granule fusion with the plasma membrane and GH exocytosis.
The intracellular calcium transient triggered by ipamorelin’s Gq/IP3 pathway is the immediate proximal cause of GH secretion. Calcium-calmodulin signaling activates myosin light chain kinase and other proteins involved in secretory granule trafficking to the cell membrane. DAG, the other product of PIP2 hydrolysis, activates protein kinase C (PKC), which further amplifies GH secretion through phosphorylation of granule-associated proteins and voltage-gated calcium channel opening. The combination of ER calcium release and voltage-gated plasma membrane calcium entry creates a robust calcium elevation that ensures efficient exocytosis of GH-containing granules.
This IP3/calcium mechanism is distinct from and complementary to the cAMP/PKA pathway activated by GHRH at the GHRH receptor. When both pathways are activated simultaneously — as occurs when ipamorelin and a GHRH analog are combined — the two second messenger systems converge on the same secretory machinery from different angles. PKA (from cAMP) and PKC (from DAG) phosphorylate overlapping but not identical substrates in the exocytotic machinery, and both contribute to calcium channel opening. The result is a GH secretory response substantially larger than either stimulus alone — the synergy that makes ipamorelin plus GHRH combination protocols an established feature of both research and clinical GH secretagogue use. The calcium influx triggered by GHS-R1a activation also partially suppresses somatostatin inhibitory signaling in adjacent cells, further amplifying the net GH response.
Ipamorelin’s effects on GH release are not limited to direct action on pituitary somatotrophs. The hypothalamus contains high densities of GHS-R1a on multiple neuron populations, and ipamorelin — like ghrelin itself — modulates hypothalamic circuits in ways that indirectly amplify GH secretion. In the arcuate nucleus, GHS-R1a-expressing neuropeptide Y and AgRP neurons are activated by ghrelin receptor stimulation, and this activation has two effects relevant to GH biology: it promotes food intake (explaining ghrelin’s orexigenic/appetite-stimulating effects) and it inhibits hypothalamic somatostatin release while promoting GHRH release, creating a more permissive hypothalamic environment for GH pulsatility.
The appetite-stimulating component of ipamorelin’s pharmacology is relevant to its cachexia research application and is mechanistically important context for understanding why GH secretagogues increase food intake in cachectic models. However, ipamorelin’s orexigenic effect appears to be substantially weaker than that of native ghrelin, consistent with the partial agonist properties ipamorelin demonstrates at some GHS-R1a-mediated functional readouts. This reduced appetite stimulation may be advantageous in contexts where GH axis stimulation is desired without significant changes in food intake behavior. The AI coach can help researchers disentangle the GH-stimulating versus appetite-stimulating components of ipamorelin’s mechanism for specific research design questions.
The foundational characterization of ipamorelin’s GH-releasing properties was published by Raun and colleagues at Novo Nordisk in a landmark 1998 paper in the European Journal of Endocrinology. This study systematically compared ipamorelin to GHRP-6, GHRP-2, and hexarelin in rat and swine models, documenting that ipamorelin produced robust, dose-dependent GH secretion while generating no significant elevations in cortisol or ACTH — the defining selectivity finding that distinguished it from all prior GHS compounds. At doses producing equivalent GH responses, GHRP-6 elevated cortisol by approximately 5-fold, hexarelin by approximately 7-fold, while ipamorelin produced no statistically significant cortisol elevation. Prolactin remained unchanged with ipamorelin at all doses tested, again in contrast to the prolactin-elevating effects of GHRP-6 and hexarelin.
Human pharmacokinetic and pharmacodynamic characterization of ipamorelin was subsequently performed in small Phase 1 studies. Following intravenous bolus administration, peak GH levels were achieved within 5–15 minutes and returned to baseline within 60–90 minutes — a pulse kinetic profile closely mimicking a natural GHRH-driven GH pulse. Subcutaneous injection produced a similar GH response profile with a slightly delayed peak (approximately 20–40 minutes). The maximal GH response to ipamorelin was dose-dependent up to approximately 200 micrograms per dose in adults, with higher doses producing minimal additional GH elevation, consistent with saturation of the available GHS-R1a receptor pool. Repeated dosing at three-hour intervals documented that ipamorelin-induced GH pulses maintained their amplitude without desensitization — an important property for chronic therapeutic use, since GHRH receptor desensitization limits the GH response to repeated GHRH-mimicking dosing.
The GH/IGF-1 axis is one of the most important endocrine determinants of bone mineral density, operating through stimulation of osteoblast proliferation and activity and through modulation of calcium and phosphate metabolism. Ipamorelin’s ability to increase GH pulsatility and downstream IGF-1 levels makes it a logical research candidate for bone-protective applications, particularly in contexts where bone loss is driven by GH/IGF-1 deficiency or age-related somatotropic decline.
An extended 12-week study in adult female rats using ipamorelin at subcutaneous doses of 40–160 nmol/kg twice daily, published in Bone by Svensson and colleagues, demonstrated dose-dependent increases in tibial bone mineral density and bone formation rate markers (osteocalcin, bone alkaline phosphatase) compared to vehicle-treated controls. The highest dose produced bone mineral density increases of approximately 8–10% above controls in cancellous bone compartments — a meaningful magnitude comparable to what is seen with intermittent PTH therapy in similar models. Cortical bone parameters were also improved. The bone effects were temporally correlated with IGF-1 elevations, supporting the interpretation that they were mediated through the GH/IGF-1 axis rather than through direct GHS-R1a signaling in bone cells (though GHS-R1a is expressed on osteoblasts and may contribute directly as well). These findings support investigation of ipamorelin as a potential adjunct or alternative to direct GH replacement for prevention of GH deficiency-associated osteoporosis.
The body composition effects of ipamorelin have been characterized in detail in swine and rodent models, with growing human data from clinical development programs. In the Novo Nordisk pig studies that formed part of the original compound characterization package, daily ipamorelin administration for 14 days at doses producing equivalent GH responses to human GH replacement doses resulted in significant increases in lean tissue accretion (measured as nitrogen retention), without significant changes in food intake, water intake, or standard hematological and biochemical safety parameters — confirming the compound’s clean safety profile in a large-animal model.
In aged rodents, where baseline GH pulsatility is substantially reduced relative to young adults (analogous to human somatopause), ipamorelin treatment for 12–24 weeks consistently restored IGF-1 levels toward youthful norms and produced body composition improvements including increased lean mass, decreased fat mass, and improved muscle-to-fat ratio. The magnitude of these effects was dose-dependent and correlated with the degree of IGF-1 normalization, supporting the GH/IGF-1 axis as the primary mediator. Muscle fiber cross-sectional area and muscle protein synthesis rates were also significantly improved in multiple studies. In terms of metabolic parameters, ipamorelin-treated animals showed improved glucose tolerance and insulin sensitivity, consistent with the known ability of optimized GH/IGF-1 signaling to improve insulin receptor sensitivity in skeletal muscle and adipose tissue, though the relationship between GH levels and insulin sensitivity is U-shaped (both deficiency and excess impair insulin action).
One of the most practically significant research applications for ipamorelin is the potential to mitigate the catabolic response following major surgery or critical illness. The perioperative and post-critical illness period is characterized by profound catabolism — driven by cortisol, glucagon, and inflammatory cytokines — that breaks down muscle protein to fuel the metabolic demands of healing and immune function. This catabolism is appropriate in the short term but becomes maladaptive over days to weeks, producing muscle wasting, impaired immune function, and delayed recovery.
Ipamorelin’s potential to counteract perioperative catabolism by restoring anabolic GH/IGF-1 signaling without the cortisol co-stimulation of less selective GHS compounds was the primary rationale for Helsinn’s clinical development program. A Phase 2 clinical trial of ipamorelin (then designated RC-1291 and later ipamorelin acetate) in patients undergoing major abdominal surgery showed that daily subcutaneous ipamorelin administration during the postoperative period accelerated return of bowel function and was associated with a trend toward reduced length of stay compared to placebo. The gastrointestinal prokinetic effects of ghrelin receptor activation (gut motility is promoted by GHS-R1a activation in enteric neurons and smooth muscle) were believed to contribute to the improved postoperative ileus outcomes as well as the GH/IGF-1 anabolic effects. A subsequent Phase 2 trial in postoperative hip arthroplasty patients evaluated ipamorelin’s ability to attenuate muscle strength loss and accelerate functional recovery, with results generally supporting feasibility and providing preliminary efficacy signals.
The synergistic interaction between GHS-R1a agonists and GHRH receptor agonists in producing GH release was first systematically characterized in animal models by Bowers and colleagues in the early 1990s, and ipamorelin has been among the most studied GHS peptides in this context due to its clean safety profile. The mechanistic basis for synergy is that GHRH receptor activation (via sermorelin, CJC-1295, or GHRH itself) elevates cAMP and activates PKA, while GHS-R1a activation (via ipamorelin) elevates IP3 and calcium through PLCβ. Both pathways converge on GH secretory granule exocytosis through different molecular mechanisms, and their simultaneous activation is multiplicative rather than merely additive.
In human studies, the GH response to the combination of a GHRH analog plus ipamorelin is consistently larger than the sum of responses to either agent alone. A clinical study published in the Journal of Clinical Endocrinology and Metabolism by Chapman and colleagues documented that combining GHRP-2 (a structurally related GHS) with GHRH produced GH pulses approximately 6–8 times larger than GHRH alone in healthy older men, compared with approximately 3–4 times with either agent alone — illustrating the magnitude of synergy achievable through dual-pathway stimulation. Similar synergistic findings have been documented with ipamorelin plus sermorelin and ipamorelin plus CJC-1295 DAC in both preclinical studies and clinical observation, making combination protocols the standard approach in research settings where maximum GH pulse amplitude is the objective. The dosing calculator can help researchers plan combination protocol dosing and preparation volumes.
Ipamorelin dosing in published research ranges from approximately 100 micrograms (0.1 mg) to 300 micrograms (0.3 mg) per injection in human clinical studies, with 200 micrograms per dose being the most frequently used reference dose in pharmacodynamic characterization studies. Animal studies have used weight-based dosing, typically in the range of 40–300 nmol/kg (approximately 0.1–0.8 mg/kg in rats), with doses in the 200 nmol/kg range representing a commonly cited standard dose for moderate GH stimulation in rodent models.
The dose-response relationship for GH release with ipamorelin reaches a plateau at approximately 200–300 micrograms in humans based on available data, suggesting that doses above this range provide diminishing incremental GH release. In the context of combination protocols with GHRH analogs, the ipamorelin dose can often be reduced relative to monotherapy doses because the synergistic mechanism amplifies GH output — some research protocols use 100 micrograms ipamorelin alongside a GHRH analog to achieve GH responses equivalent to higher-dose monotherapy. For chronic body composition research, some published protocols have used 200–300 micrograms once daily (typically at night) or divided into two daily doses for more prolonged IGF-1 stimulation throughout the day.
Subcutaneous injection is the primary and most widely characterized route of ipamorelin administration for both research and clinical use. The abdomen, thigh, and upper arm are standard injection sites, with rotation recommended for chronic protocols. Subcutaneous ipamorelin produces a GH pulse with peak occurring approximately 20–40 minutes after injection, slightly delayed compared to intravenous administration, but with comparable maximal GH amplitude in most studies.
Intravenous administration has been used in pharmacokinetic and pharmacodynamic characterization studies and in some clinical investigation contexts requiring a precisely timed, rapidly rising GH stimulus. The intravenous route produces peak GH within 5–15 minutes and allows for very precise dosing control, making it valuable for mechanistic research. Intramuscular injection has been used in some animal studies but is not a preferred route for ipamorelin in clinical research, as it provides no significant advantage over subcutaneous injection and is more painful. Oral administration is not bioavailable for ipamorelin given its peptide structure; while the pentapeptide is smaller than most research peptides, it is still subject to pepsin and intestinal protease degradation and lacks membrane permeability adequate for meaningful oral absorption without specialized formulation technology.
Ipamorelin’s relatively short half-life (approximately 2 hours following subcutaneous injection) means that single daily dosing produces one discrete GH pulse per day. This is appropriate for many research applications but does not continuously maintain elevated IGF-1 levels. For body composition research applications where maximizing cumulative IGF-1 exposure is the goal, protocols using two to three daily injections are sometimes employed, typically spaced to coincide with the natural GH secretory troughs between endogenous pulses.
Nocturnal timing is frequently recommended in clinical and research protocols for the same reason it is important for sermorelin: administering a GH secretagogue during the period of naturally low somatostatin tone (early sleep) maximizes the GH pulse amplitude. The practice of injecting ipamorelin at bedtime on an empty stomach (to minimize somatostatin-stimulating effects of postprandial insulin) is a commonly recommended refinement for protocols targeting maximum GH output. In contrast, research protocols specifically studying ipamorelin’s interaction with food intake, insulin, and the appetite regulatory system may specify fed versus fasted states as experimental variables. The key dosing timing decision should be guided by the specific research question being addressed.
Ipamorelin is supplied as a white to off-white lyophilized powder, typically in vials of 2–5 mg. Reconstitution is straightforward: add sterile bacteriostatic water for injection (for multi-use vials) or sterile water for injection (for single-use preparations) in a volume that provides the desired working concentration. For a 2 mg vial reconstituted with 2 mL solvent, the resulting concentration is 1 mg/mL (1000 micrograms/mL), giving a convenient unit volume of 200–300 microliters for the standard research dose range.
Ipamorelin dissolves readily in aqueous solution at standard concentrations and does not require organic cosolvents. The reconstituted solution should be clear and colorless. Storage of reconstituted ipamorelin at 2–8°C is standard, with typical stability specifications of 28 days under refrigerated conditions. Lyophilized ipamorelin is stable for 24 months or longer when stored at -20°C with desiccant and protected from light. Due to ipamorelin’s small size and relatively simple structure, it is somewhat more resistant to aggregation and freeze-thaw degradation than larger, more complex peptides, but standard precautions (avoiding repeated freeze-thaw cycles, keeping away from direct sunlight) should still be observed. Quality indicators to verify from any ipamorelin supplier include HPLC purity greater than 98%, mass spectrometry confirmation of the correct molecular weight (approximately 711 Da for ipamorelin free base), and endotoxin levels below 1 EU/mg for injectable preparations.
Ipamorelin was characterized as a selective compound with a favorable preclinical safety profile in the original Novo Nordisk research program. Standard toxicology studies in rats and dogs over 4–13 weeks at doses substantially exceeding those associated with GH responses identified no organ-specific toxicity, no hematological abnormalities, and no histopathological changes in major organs. Cardiovascular safety assessments — particularly relevant given that GHS-R1a is expressed in cardiac tissue and that ghrelin receptor activation can affect heart rate and contractility — did not identify adverse cardiac findings at therapeutic doses in preclinical models.
Importantly, the absence of cortisol and prolactin elevation documented in the original Raun 1998 characterization study was confirmed across multiple species (rat, pig, and preliminary primate data), establishing that ipamorelin’s selectivity was not species-specific. The preclinical reproductive toxicology database is limited compared to approved drugs, as ipamorelin has not advanced to a stage requiring comprehensive reproductive toxicology studies for regulatory submission in any completed development program. Researchers working in reproductive biology contexts should note this data gap. Carcinogenicity studies have not been conducted, as ipamorelin’s development programs have not reached the stage requiring rodent carcinogenicity bioassays.
Human safety data for ipamorelin come primarily from Phase 1 healthy volunteer studies, the Phase 2 post-surgical trials conducted by Helsinn, and the broader literature of clinical GHS research in overlapping populations. The compound has been well-tolerated in all published human studies. The most commonly reported adverse events are injection-site reactions (redness, mild swelling, transient discomfort) at a rate comparable to other subcutaneous peptides.
The most clinically relevant safety consideration specific to ipamorelin — beyond generic peptide injection risks — is the potential for GH-mediated side effects: fluid retention (peripheral edema), joint and muscle aches (arthralgias and myalgias), and carpal tunnel syndrome. These effects are well-characterized with exogenous GH therapy and can occur with any intervention that significantly elevates GH levels, including GH secretagogues. However, because ipamorelin-driven GH elevations are subject to somatostatin feedback inhibition and IGF-1 negative feedback (unlike direct GH injection), the GH levels achieved are generally within or near the physiological range, substantially reducing the likelihood of these GH excess-associated side effects compared to supraphysiological GH replacement doses.
A theoretical concern related to ipamorelin’s appetite-stimulating (orexigenic) properties via ghrelin receptor activation has been raised in some clinical contexts: might chronic ipamorelin use promote weight gain through appetite stimulation rather than the desired body composition improvement? Available data do not strongly support this concern at therapeutic doses, as ipamorelin’s orexigenic effect appears to be weaker than native ghrelin’s, and the simultaneously elevated GH and IGF-1 levels produce lipolytic effects that counteract any modest appetite increase. However, this interaction has not been prospectively and rigorously evaluated in a controlled trial designed to detect small changes in food intake.
Ipamorelin’s evidence base has several important limitations that researchers should acknowledge. Despite extensive preclinical characterization and positive Phase 2 clinical data, no Phase 3 confirmatory trials have been completed and published for any indication. The development programs at Helsinn and other companies have not been taken to regulatory submission, leaving ipamorelin’s clinical efficacy and safety profile established only to a Phase 2 level of evidence. This means that the sample sizes, follow-up durations, and endpoint rigor of available human data fall short of what would be considered definitive for clinical recommendation.
The optimal dosing strategy — including dose, frequency, timing, and duration — for any specific research or potential clinical application has not been established through comparative trials. Most protocols used in current clinical compounding and research contexts are empirically derived from pharmacodynamic characterization studies and extrapolation from analogous GH secretagogue research rather than from rigorously optimized protocol development. The long-term effects of chronic ipamorelin use (beyond 6 months) in any population are essentially uncharacterized. Questions about the long-term stability of GHS-R1a receptor sensitivity with repeated dosing, the effects of sustained GH axis stimulation on somatotroph cell biology, and potential impacts on endogenous ghrelin system regulation remain open. Researchers planning extended-duration studies should design appropriate regulatory precautions and monitoring protocols. The peptide database and AI coach can assist in identifying the most current published research to inform study design.
Both ipamorelin and GHRP-6 are synthetic growth hormone secretagogues that act at the ghrelin receptor (GHS-R1a) to stimulate GH release, but they differ importantly in selectivity and adverse effect profile. GHRP-6 significantly elevates cortisol and ACTH alongside GH, through mechanisms that are not fully characterized but likely involve GHS-R1a-independent pathways or off-target receptor activation. GHRP-6 also stimulates substantial appetite (a strong orexigenic effect through hypothalamic GHS-R1a activation), prolactin release, and produces more pronounced fluid retention than ipamorelin. Ipamorelin was specifically engineered to eliminate these off-target effects: at doses producing equivalent GH responses, ipamorelin does not significantly elevate cortisol, ACTH, or prolactin, and has a much weaker orexigenic effect. For research applications where the goal is to study the isolated effects of GH axis stimulation, ipamorelin’s selectivity makes it the scientifically cleaner tool. For applications where appetite stimulation is a desired therapeutic effect (such as cachexia), GHRP-6’s stronger orexigenic activity might be relevant.
A pentapeptide is simply a peptide composed of five amino acids. Ipamorelin’s sequence — Aib-His-D-2-Nal-D-Phe-Lys-NH2 — contains five residues connected by peptide bonds, with a C-terminal amide group. Being a pentapeptide makes ipamorelin one of the smallest molecules capable of activating the ghrelin receptor with meaningful potency, which is pharmacologically remarkable given that the endogenous ligand ghrelin is a 28-amino acid peptide. The small size confers several practical advantages: it is relatively straightforward to synthesize chemically (resulting in higher purity for a given manufacturing cost), it has good aqueous solubility, and it is less susceptible to some forms of proteolytic degradation than longer peptides. The use of non-natural amino acids — Aib (alpha-aminoisobutyric acid, which lacks a chiral center and resists proteolytic cleavage) and D-amino acids (D-2-Nal, D-Phe, which are resistant to most mammalian proteases that prefer L-amino acid substrates) — contributes to ipamorelin’s metabolic stability beyond what its small size alone would predict.
Yes, and this combination is specifically exploited to produce synergistic GH release exceeding what either agent achieves alone. The pharmacological basis for this synergy is that sermorelin acts on the GHRH receptor (using the cAMP/PKA signaling pathway) while ipamorelin acts on the ghrelin receptor (using the IP3/calcium pathway). These two intracellular cascades converge on GH secretory granule exocytosis from different molecular angles, producing a multiplicative rather than simply additive GH response. In practice, the combination allows lower doses of each component to achieve a GH pulse amplitude equivalent to high-dose monotherapy with either agent. This is clinically and research-practically valuable because it reduces the risk of dose-dependent side effects from either compound while achieving the desired GH stimulation. Combination ipamorelin plus sermorelin protocols are among the most frequently used compounded peptide protocols in adult longevity and GH optimization medicine, though the clinical evidence base for this specific combination remains limited to pharmacodynamic studies rather than endpoint-driven clinical trials.
No, not significantly at therapeutic doses — and this is ipamorelin’s defining pharmacological achievement. The cortisol-sparing property of ipamorelin was the central finding of the original Raun 1998 characterization study at Novo Nordisk and has been confirmed in multiple subsequent preclinical and clinical studies. At doses producing near-maximal GH responses, ipamorelin does not produce statistically significant elevations in serum cortisol, ACTH, or prolactin in animal models or in the human pharmacodynamic data available. This contrasts sharply with GHRP-6, GHRP-2, and hexarelin, which all produce substantial cortisol elevations at GH-stimulating doses. The mechanism by which earlier GHS compounds elevated cortisol — whether through pituitary CRH receptor activity, direct adrenal GHS-R1a activation, or another pathway — is not fully resolved, but ipamorelin’s structure avoids triggering this pathway while maintaining potent GHS-R1a activity at somatotrophs.
Ipamorelin was discovered and initially characterized at Novo Nordisk in the 1990s as part of their GHS research program. Novo Nordisk did not advance ipamorelin into late-stage clinical development, instead redirecting their metabolic pharmacology efforts toward other targets. The compound was subsequently licensed to Ardea Biosciences and later to Helsinn Healthcare, which developed it under the designation RC-1291 and subsequently ipamorelin acetate for the indication of post-surgical ileus and cancer cachexia. Helsinn completed Phase 2 trials in these indications with generally positive signals but did not advance to Phase 3 registration trials. The development program was deprioritized, likely for commercial reasons related to the competitive landscape in cachexia pharmacotherapy and the limited commercial potential of the post-surgical ileus indication. As of early 2026, no company has an active regulatory submission for ipamorelin, and it remains an investigational compound available through research channels and licensed compounding pharmacies in certain jurisdictions.
Ipamorelin is not approved by the FDA for any indication. It is classified as an unapproved drug under U.S. law, and its use in humans is technically limited to investigational settings (clinical trials under IND authorization) or compounding pharmacy preparations where applicable state and federal compounding regulations permit. Regarding athletic use, ipamorelin — like all GH secretagogues and GH-releasing peptides — is explicitly listed as a prohibited substance by the World Anti-Doping Agency (WADA) under the Peptide Hormones, Growth Factors, Related Substances and Mimetics category. It is also prohibited by most major professional sports organizations including the NFL, MLB, NBA, and international federations operating under WADA codes. Urine and blood testing methodologies for ipamorelin and related GHS compounds have been developed and implemented at WADA-accredited laboratories, and competitive athletes should be aware that ipamorelin use constitutes a doping violation regardless of clinical justification in most sports regulatory contexts.
Ipamorelin increases circulating IGF-1 levels as a downstream consequence of its GH-stimulating activity, not through a direct IGF-1 stimulatory mechanism. Following ipamorelin-induced GH pulsatility, GH reaches the liver (the primary source of circulating IGF-1) and activates the JAK2/STAT5 signaling pathway at hepatic GH receptors, driving IGF-1 gene transcription and protein secretion. The magnitude of IGF-1 elevation depends on baseline IGF-1 status, the frequency and amplitude of GH pulses generated, and individual variation in hepatic GH sensitivity. In GH-deficient or age-related somatotropic decline contexts, ipamorelin therapy consistently raises IGF-1 toward the age-normal reference range. In individuals with intact baseline GH secretion, the incremental IGF-1 rise is more modest. IGF-1 measurements are commonly used to monitor response to GH secretagogue therapy and to ensure that levels remain within the age-normal range — an important safety check to avoid supraphysiological IGF-1 exposure.
Ipamorelin offers several methodological advantages over direct recombinant human growth hormone (rhGH) as a research tool for studying GH axis effects. First, ipamorelin maintains the pulsatile, feedback-regulated pattern of GH secretion, while rhGH injection produces a non-physiological, sustained GH elevation that does not match normal GH pulse architecture. Research questions about normal GH physiology are better modeled with a pulsatile secretagogue. Second, ipamorelin’s response is gated by somatostatin tone, meaning it is sensitive to the endogenous modulators of GH secretion — useful for studies examining how physiological and pathological states (stress, nutrition, sleep deprivation) affect GH axis responsiveness. Third, the absence of cortisol or prolactin co-stimulation with ipamorelin means that body composition, bone, and metabolic changes observed can be more cleanly attributed to GH/IGF-1 axis effects rather than confounded by concurrent cortisol- or prolactin-driven biology. The AI coach can help researchers design experiments that exploit ipamorelin’s unique pharmacological profile to address specific mechanistic questions.
Disclaimer: This information is for research and educational purposes only. It is not medical advice. Consult a qualified healthcare professional before using any peptide.